我们也证实,序贯灌注 gemcitabine 与 docetaxel——两种化疗药物先后灌注入膀胱——对中风险病变而言,是替代 BCG 的合理选择。我们目前正在英国的一项大型随机临床试验中(COBRA),评估这种方法用于高风险膀胱癌的效果,该试验由 National Institute for Health Research 资助。
Cambier S, Sylvester RJ, Collette L, et al. EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance bacillus Calmette-Guérin. Eur Urol. 2016;69(1):60-9. PMID 26210894。
Tan WS, Steinberg G, Witjes JA, et al. Intermediate-risk Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group. Eur Urol Oncol. 2022;5(5):505-516. PMID 35718695。
Tan WS, Contieri R, Buffi NM, et al. International Bladder Cancer Group Intermediate-risk Nonmuscle-invasive Bladder Cancer Scoring System Predicts Outcomes of Patients on Active Surveillance. J Urol. 2023;210(5):763-770. PMID 37535836。
Tan WS, McElree IM, Davaro F, et al. Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. 2023;6(5):531-534. PMID 37468392。
Tan WS, Grajales V, Contieri R, et al. Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes. Eur Urol Open Sci. 2023;53:16-22. PMID 37441349。
Tan WS, Grajales V, Bree K, et al. Bacillus Calmette-Guérin (BCG) unresponsive non-muscle-invasive bladder cancer: are the subgroups equal? BJU Int. 2023;132(4):384-386. PMID 37246493。
Grajales V, Contieri R, Tan WS, et al. Comparative Analysis of Very Reduced vs Full Dose BCG Treatment for High-Risk Non-Muscle Invasive Bladder Cancer: A Contemporary Experience from Chile. Bladder Cancer. 2023;9(4):327-334. PMID 38994240。
Tan WS, Prendergast A, Ackerman C, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. 2022;83(6):497-504. PMID 35999119。
Tan WS, Panchal A, Buckley L, et al. Radiofrequency-induced thermo-chemotherapy effect versus a second course of bacillus Calmette-Guérin or institutional standard in patients with recurrence of non-muscle-invasive bladder cancer following induction or maintenance bacillus Calmette-Guérin therapy (HYMN): a phase III, open-label, randomised controlled trial. Eur Urol. 2019;75(1):63-71. PMID 30274699。
Tan WS, Kelly JD Intravesical device-assisted therapies for non-muscle-invasive bladder cancer. Nat Rev Urol. 2018;15(11):667-685. PMID 30254383。
延伸指南与病人资料:COBRA 试验: icr.ac.uk — COBRA · American Urological Association (AUA/SUFU); British Association of Urological Surgeons (BAUS) patient information; Cancer Research UK; National Comprehensive Cancer Network (NCCN); UpToDate.